Latest California Healthline Stories
Buried In Congress’ Opioid Bill Is Protection For Personal Drug Imports
The protection is a win for people who get their needed, legitimate drugs from overseas.
Readers And Tweeters Slice And Dice Precision Medicine, Step Therapy
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Sobredosis de opioides en el trabajo, una realidad que empleadores ignoran
En ciertas industrias, como la de la construcción, el consumo de opioides es una constante con la que pocos empleadores están preparados para lidiar.
Workers Overdose On The Job, And Employers Struggle To Respond
Despite the growing epidemic of Americans misusing opioids and overdosing on the job, many employers turn a blind eye to addiction within their workforce — ill-equipped or unwilling to confront an issue they are at a loss to handle.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
New Medicare Advantage Tool To Lower Drug Prices Puts Crimp In Patients’ Choices
Federal officials are allowing the private insurance plans to use “step therapy” for drugs administered by doctors. In step therapy, patients must first use cheaper drugs to see if they work before receiving more expensive options.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Insulin’s Steep Price Leads To Deadly Rationing
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn’t afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.